News

The FDA approval of Elelyso for the treatment of type 1 Gaucher disease has triggered the payment. Pfizer and Protalix signed an exclusive license and supply agreement relating

The solution deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and devices studies in many languages across the world. POI

knomeclinic when upgraded to Early Access Program will have a robust, scalable, and extensible informatics and annotation platform,zkGAP, Desktop interpretation-support application, Knowledge database and Curation applications. Knome chief

Dako’s HercepTest and HER2 FISH pharmDx Kit are used to recognise cancer patients with HER2-positive metastatic breast cancer, who may be eligible for Perjeta treatment. Pertuzumab, which received

The approval is based on a Phase III study in which combination of Perjeta, Herceptin and chemotherapy demonstrated a significant improvement in PFS compared to Herceptin plus chemotherapy

The purpose of the commercial royalty-bearing license is to conduct a larger scale market evaluation. The licensee has agreed to rental and royalty terms allowing them to install

Baricitinib is an orally administered selective JAK1 and JAK2 inhibitor that is JAK3-sparing. A total of 301 patients, with active RA on stable doses of methotrexate, were randomized

According to the agreement, a variety of glucagon presentations will be developed and commercialized including Biodel’s glucagon product candidate, a liquid formulation in an auto injector intended for

Dificlir, indicated to treat Clostridium difficile infections (CDI), is an orally administered, macrocyclic antibiotic that was developed by Optimer Pharmaceuticals. Astellas gained rights to develop and commercialize Dificlir